BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Hangzhou Zhongmei Huadong Pharmaceutical readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Hangzhou Zhongmei Huadong Pharmac
 eutical's drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07521631-196@assetmemo.bio
DTSTAMP:20261121T010025Z
DTSTART;VALUE=DATE:20270204
DTEND;VALUE=DATE:20270205
SUMMARY:HDM1005: Phase 2 readout est. (NCT07521631)
DESCRIPTION:HDM1005\, phase 2\, Obesity.\nStudy: Efficacy and Safety of HDM
 1005 Compared to Tirzepatide in Obese Adults Without Diabetes\nEstimated p
 rimary completion: 4 February 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/hdm1005#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07521631
URL:https://assetmemo.bio/drug/hdm1005#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07082114-195@assetmemo.bio
DTSTAMP:20261121T010025Z
DTSTART;VALUE=DATE:20270216
DTEND;VALUE=DATE:20270217
SUMMARY:HDM1002: Phase 3 readout est. (NCT07082114)
DESCRIPTION:HDM1002\, phase 3\, Type 2 Diabetes.\nStudy: A Phase 3 Study to
  Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Dia
 betes Mellitus\nEstimated primary completion: 16 February 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/hdm1002#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07082114
URL:https://assetmemo.bio/drug/hdm1002#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07394114-196@assetmemo.bio
DTSTAMP:20261121T010025Z
DTSTART;VALUE=DATE:20270828
DTEND;VALUE=DATE:20270829
SUMMARY:HDM1005: Phase 3 readout est. (NCT07394114)
DESCRIPTION:HDM1005\, phase 3\, Type 2 Diabetes.\nStudy: A Study of HDM1005
  in Participants With Type 2 Diabetes Not Controlled With Diet and Exercis
 e Alone\nEstimated primary completion: 28 August 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/hdm1005#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07394114
URL:https://assetmemo.bio/drug/hdm1005#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07417306-196@assetmemo.bio
DTSTAMP:20261121T010025Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:HDM1005: Phase 3 readout est. (NCT07417306)
DESCRIPTION:HDM1005\, phase 3\, Type 2 Diabetes.\nStudy: A Study of HDM1005
  in Participants With T2DM Not Controlled With Metformin Alone or in Combi
 nation With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor\nEstimated 
 primary completion: 30 August 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/hdm1005#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07417306
URL:https://assetmemo.bio/drug/hdm1005#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07787260-196@assetmemo.bio
DTSTAMP:20261121T010025Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:HDM1005: Phase 3 readout est. (NCT07787260)
DESCRIPTION:HDM1005\, phase 3\, Obesity.\nStudy: A Phase III\, Multicenter\
 , Randomized\, Double-Blind\, Placebo-Controlled Clinical Study to Evaluat
 e the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructiv
 e Sleep Apnea (OSA) and Obesity Not Receiving Positive Airway Pressure (PA
 P) Therapy\nEstimated primary completion: March 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/hdm1005#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07787260
URL:https://assetmemo.bio/drug/hdm1005#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07794397-196@assetmemo.bio
DTSTAMP:20261121T010025Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:HDM1005: Phase 3 readout est. (NCT07794397)
DESCRIPTION:HDM1005\, phase 3\, Obesity.\nStudy: A Phase III\, Multicenter\
 , Randomized\, Double-Blind\, Placebo-Controlled Clinical Study to Evaluat
 e the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructiv
 e Sleep Apnea (OSA) and Obesity Receiving Positive Airway Pressure (PAP) T
 herapy\nEstimated primary completion: September 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/hdm1005#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07794397
URL:https://assetmemo.bio/drug/hdm1005#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
